(2) There is an urgent need for large-scale clinical trials to ascertain the therapeutic efficacy and safety of SIRT1 modulators in patients with PAH, particularly in advanced disease stages, as these outcomes may be significantly influenced by sex and the presence of obesity, including long-term investigations. The gene discussed is SIRT1; the disease is obesity due to melanocortin 4 receptor deficiency.